15-PGDH Modulator Compositions for Tissue-Specific Prostaglandin Control
Solution Overview
Problem
Current therapies for modulating short-chain dehydrogenase (SCD) activity, particularly 15-PGDH, are limited in effectively addressing conditions related to prostaglandin levels and associated disorders such as colon tumors, thrombin-mediated cell death, and conditions benefiting from PGE2 activity like hair density and dermal wound healing.
Innovation Solution
Development of specific 15-PGDH inhibitors and activators that can modulate prostaglandin levels by inhibiting or activating the enzyme, utilizing compounds with defined structural formulas to target SCD activity in tissues or blood, thereby influencing prostaglandin levels and treating related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 15-PGDH enzyme activity is increased to inactivate prostaglandins, then prostaglandin levels decrease, but beneficial effects on hair density, dermal wound healing, and bone formation are reduced
Solution Approach 1:
The patent applies local quality by developing tissue-specific 15-PGDH modulators that can selectively increase enzyme activity in certain tissues (e.g., colon, lung, liver) while maintaining or preserving prostaglandin levels in other tissues (e.g., skin, bone, hair follicles). This allows differential control of prostaglandin metabolism in different anatomical locations, enabling therapeutic benefits in target tissues without compromising beneficial effects in non-target tissues.
2Object-affected harmful factors
If 15-PGDH inhibitors are used to increase prostaglandin levels, then beneficial effects on hair growth and wound healing improve, but risk of colon tumor development increases
Solution Approach 1:
The patent segments the therapeutic effect by creating compounds that selectively modulate 15-PGDH activity in specific tissues. The segmented approach allows increasing prostaglandin levels in tissues requiring beneficial effects (skin, hair follicles) while maintaining low prostaglandin levels in colon tissue to prevent tumor development. This is achieved through tissue-specific pharmacokinetic properties or selective receptor binding of the modulators.
Solution Approach 2:
The patent applies local quality by developing modulators with differential tissue distribution and selectivity. The compounds are designed to accumulate or exert greater effect in specific tissues (e.g., skin for wound healing, hair follicles for hair growth) while having minimal impact on colon tissue. This spatially differentiated modulation resolves the contradiction between beneficial effects and tumor risk.
3Adaptability or versatility
If broad-spectrum SCD inhibitors are used to treat multiple disorders, then therapeutic versatility improves, but off-target effects and side effects increase
Solution Approach 1:
The patent applies local quality by developing SCD modulators with tissue-specific selectivity. Each compound is designed to preferentially modulate 15-PGDH activity in specific tissues relevant to the targeted indication (e.g., lung tissue for COPD, liver tissue for metabolic disorders, skin tissue for wound healing). This tissue-specific action provides therapeutic versatility across multiple disorders while minimizing off-target effects by avoiding broad-spectrum inhibition.
Solution Approach 2:
The patent uses tissue-specific transporters, binding proteins, or metabolic pathways as intermediaries to deliver the SCD modulators selectively to target tissues. These intermediaries facilitate preferential accumulation or activation of the compounds in specific organs, enabling broad therapeutic applicability while maintaining selectivity and reducing off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 15-PGDH inhibitors enhance prostaglandin levels, promoting hair growth, wound healing, and tissue regeneration, while treating conditions like oral ulcers, colitis, and enhancing the therapeutic effect of prostanoid agonists, thus addressing a range of health issues.
Implementation Method 1
catalyzing oxidation of PGE2 to 15-keto-prostaglandin E2, 15k-PGE
Implementation Method 2
inhibitors of 15-PGDH...could be therapeutically valuable
Data Source
AI summary
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.